UCB lands EU approval for first TK2 deficiency therapy Kygevvi

Belgian biopharma UCB (Euronext Brussels: UCB) has secured European Commission approval for Kygevvi (doxecitine/doxribtimine), the first authorized treatment for thymidine kinase 2 deficiency, a rare and often fatal mitochondrial disease.

The drug is cleared for pediatric and adult patients with genetically confirmed disease and symptom onset at or before 12 years. Approval was granted under exceptional circumstances, reflecting the condition’s rarity and limited clinical data.